BrandArena: Sanofi Nigeria reinforces its commitment to diabetes through new treatment

Monday 2 February 2015

Sanofi Nigeria reinforces its commitment to diabetes through new treatment

With the introduction of INSUMAN, a leading Human Insulin product from Sanofi’s range of diabetes treatments, Sanofi is now the only company to provide a full range of both oral and injectable treatments for patients with diabetes in Nigeria.

To better support the patients in the management of their disease, Sanofi has also announced their support in the opening of 12 dedicated diabetes and hypertension clinics in partnership with health authorities. The first clinic was recently inaugurated, at Lagos State University Teaching Hospital.
Sales Director, Nigeria, Sanofi, Akinbowale Oluwale; Ethical Franchise Director, Nigeria-Ghana, Odediran Folake ; Director of Hospital Administration, Lagos State  Teaching Hospital (LASUTH), Mrs. Akinlawon Jumoke ; Head of Medical and Regulatory, Sanofi Nigeria-Ghana, Dr. Inoussa Fiffen; Director of Account , Lagos State  Teaching Hospital (LASUTH), Mrs. Lawal Kuburat and Assistant Director of Nursing Services, Lagos State  Teaching Hospital (LASUTH), Mrs. Shode Modupe at the donation of diabetes equipment in support of  Sanofi’s creation of diabetes & hypertension clinics held in Lagos State Teaching Hospital (LASUTH) last, Friday, January 30, 2015
In Nigeria, around 5 million people are suffering from diabetes and this figure is expected to double within the next 20 years, with 63% undiagnosed and many that are diagnosed, not correctly controlled. 76% of deaths due to diabetes are in people under the age of 60 on the African continent.

Patients are exposed to many complications including vascular complications, blindness and limb amputation, which can be prevented by treatment with Insulin and effective, close management of patients. With over 90 years’ experience in developing and manufacturing Insulin, Sanofi is a world leader in delivering quality, innovative solutions to meet the needs of patients. The INSUMAN® range allows for individualized treatment (basal, rapid and premix) available in both Vials and Cartridges.

The INSUMAN® cartridges use a unique innovative technology that ensures a more accurate dosing. In Nigeria, it will be used with the award-winning ALLSTAR™ disposable pen for delivery. “The introduction of INSUMAN® in combination with ALLSTAR™ in Nigeria demonstrates our commitment to patients, improving access and ensuring availability to high-quality, efficacious solutions to improve the management of diabetes for patients.

INSUMAN has been licensed in 90 countries and is manufactured to the highest international standards in Germany. Since its first introduction 17 years ago, more than 5 million patient-years with INSUMAN have been accumulated.

“Combining the range with ALLSTAR™, a new, disposable, injection pen will help make the lives of patients easier in Nigeria with a simple, safe to use and affordable solution”, said Abderrahmane Chakibi, General Manager, Sanofi Nigeria-Ghana Commenting on the support of the 12 new clinics in diabetes, he added ‘Delivering innovative treatments and a full portfolio adapted to the needs of patients locally is at the core of what we, at Sanofi, have done for nearly a century. But medications alone are not enough. For many years, we have been supporting healthcare professionals in their daily practice through training and tailored services.

In 2015, across Nigeria, we will support the creation of 12 clinics for Diabetes and 2/2 Hypertension in partnership with health authorities. These clinics will be established in dedicated healthcare centers to increase screening, disease awareness and patient education. They will also provide better management and monitoring of people with diabetes though dedicated nursing and physician support.

“In 2016, we aim to deploy 24 more clinics” Mr. Chakibi added. The availability of the new range of human insulin INSUMAN®, the injection pen ALLSTAR® and the support of clinics for the better management of the disease is in direct response to the healthcare needs of patients with diabetes in Nigeria.

No comments:

Post a Comment